sefulness of Timolol in a condition of vascular overgrowth of tissue
Phase 4
- Conditions
- Health Condition 1: L980- Pyogenic granuloma
- Registration Number
- CTRI/2019/04/018581
- Lead Sponsor
- Indian Association of Dermatologists Venereologists and Leprologists Research grant
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
i.Clinically diagnosed cases of pyogenic granuloma over skin
ii.Age 2 years to 65 years
iii.Patients consenting/ assenting to participate in the trial and come for follow â?? up visits
iv.Duration of skin lesion not more than 8 weeks
Exclusion Criteria
i.Age less than 2 years or more than 65 years
ii.Mucosal pyogenic granuloma
iii.Pregnant or lactating patients
iv.Systemic comorbidities like cardiac problems (sinus bradycardia, 2nd or 3rd degree AV block, overt cardiac failure, cardiogenic shock), bronchial asthma, COPD, persistent hypoglycemia
v.Patient on systemic beta-blockers, calcium channel blockers, quinidine, which have a significant interaction with topical timolol.
vi.Use of any other treatment modality previously
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method